Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026958 · ClinicalTrials.gov registry record · Phase 2
Clarithromycin Mechanisms in Hypersomnia Syndromes
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT04026958 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 83 participants.
The verdict
NCT04026958, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a medication called clarithromycin for treating sleepiness in narcolepsy and idiopathic hypersomnia. Studies have shown that clarithromycin can reduce sleepiness, but researchers do not know how clarithromycin does this. This study will look at brain activity (on magnetic resonance imaging \[MRI\]), inflammation, bacteria living in the gut, and cerebrospinal fluid, to better understand how clarithromycin can reduce sleepiness. This study will recruit 92 participants who will be randomized to receive clarithromycin or a placebo for 14 days.
Interventions
- DRUG Placebo
- DRUG Clarithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2025-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026958
The ClinicalTrials.gov registry entry for NCT04026958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04026958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04026958 about?
NCT04026958 is a clinical study titled "Clarithromycin Mechanisms in Hypersomnia Syndromes". The purpose of this study is to evaluate a medication called clarithromycin for treating sleepiness in narcolepsy and idiopathic hypersomnia. Studies have shown that clarithromycin can reduce sleepiness, but researchers do not know how clarithromycin does this. This study will look at brain activity...
What is the current status of trial NCT04026958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2019-09-04. Estimated completion is 2025-06-18.
What interventions are being tested in trial NCT04026958?
The interventions under investigation include: Placebo (DRUG), Clarithromycin (DRUG).
Who is sponsoring clinical trial NCT04026958?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.